Skip to main content

Table 1 Patient characteristics

From: Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy

 

Patients

N = 33

Febrile episodes

N = 47

MCGa

SCGb

  

N = 31 (66.0%)*

N = 16 (34.0%)*

Median age at oncologic diagnosis in years (25th–75th quartile)

8.65 (3.75–14.54)

Median age at febrile episode in years (25th–75th quartile)

8.56 (3.20–13.42)

12.99 (6.86–16.64)

Male gender (percentage)

N = 17 (51.5%)

N = 17 (54.8%)**

N = 7 (43.8%)**

Hematological malignancies (percentage)

N = 22 (66.67)

N = 16 (51.6%)**

N = 11 (68.8%)**

Solid malignancies (percentage)

N = 11 (33.33)

N = 15 (48.4%)**

N = 5 (31.2%)**

Median Leucocytes ×109 day 1 (n = 20/14) (25th–75th quartile)

0.54 (0.20–1.23)

0.40 (0.20–0.75)

Median Leucocytes x109 day 4 (n = 25/15) (25th–75th quartile)

1.40 (0.70–2.95)

0.30 (0.20–0.65)

Median Leucocytes x109 day 7 (n = 18/13) (25th–75th quartile)

3.95 (2.33–6.98)

0.50 (0.30–1.75)

Median CRP (mg/dl) day 1 (n = 14/8) (25th–75th quartile)

47.30 (18.03–101.00)

87.55 (23.05–166.00)

Median CRP (mg/dl) day 4 (n = 10/7) (25th–75th quartile)

23.60 (17.30–62.78)

96.00 (93.60–226.00)

Median CRP (mg/dl) day 7 (n = 6/5) (25th–75th quartile)

13.70 (2.85–98.73)

61.10 (29.80–81.80)

Duration of Hospitalization in days (n = 24/9) (25th–75th quartile)

7 (4.5–8)

15 (9–16)

  1. * Percent of total number. ** Percent of N = 31 (MCG) and N = 16 (SCG), respectively
  2. aMild course group
  3. bSevere course group